Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDR-101 for Immune Tolerance in Kidney Transplant
NCT03363945Phase 3Completed
- Sponsor
- Medeor Therapeutics
- Start
- Mar 2018
- Primary completion
- Apr 2024
- Modality
- Hematopoietic Stem Cells, Native Immune Cells
- Countries
- 2
01
Overview
A Phase 3 trial of sizavaleucel in kidney transplant rejection, sponsored by Medeor Therapeutics. Started Mar 2018; status: completed.
02
Drugs
sizavaleucel
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03363945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03363945.